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sonal interviews with physicians. RESULTS: Prescriptions
for 276 patients (66% women), average age 56 years
(18–88), were collected from 20 specialists. A total of 249
patients had RA (90%), 15 OA (5%) and 12 both (4%).
Fifty-three percent were celecoxib prescriptions, 47%
rofecoxib. Eighty-four percent of 117 rofecoxib prescrip-
tions to RA patients were of 25mg strength. Of these,
95% were dosed 1 ¥ 1 and the average daily number of
tablets was 1.05. Ninety-four percent of 132 celecoxib
prescriptions to RA patients were of 200mg strength. 
Of these, 68% were dosed 1 ¥ 2, and the average daily
number of tablets was 1.86. The average weighted cost
per day for celecoxib was NOK 16.75, and 11.78 for
rofecoxib (pharmacy selling prices). CONCLUSION:
This study by itself does not allow for an assessment of
the drugs’ relative cost-effectiveness. However, the pre-
scription pattern observed among specialists for reim-
bursed cox-2 inhibitors for RA patients indicates a higher
daily drug cost for celecoxib than for rofecoxib.
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OBJECTIVE: Variability in dosing of biologic agents
among patients with rheumatoid arthritis (RA), and asso-
ciated economic impact, is of great interest to payers and
providers. We examined dosing patterns for patients with
RA who were newly treated with inﬂiximab or etanercept
as well as corresponding 1-year costs of care.
METHODS: Integrated pharmacy and medical claims
data were obtained from 61 U.S. health plans. Patients
with a diagnosis of RA who were newly treated with
inﬂiximab or etanercept from July 1999 to June 2002
were selected. Among inﬂiximab patients, a maintenance
number of vials was determined after the “loading
period” (2–3 infusions); those with ≥2 occurrences of an
increase in vials or an interval between infusions of <49
days were considered to have had escalated. For etaner-
cept patients, a maintenance dose was measured on the
second prescription based on the average daily dose dis-
pensed (in mg); those with ≥2 instances of increased
average doses were considered to have escalated their
dose. RA-related costs at one year post-initiation were
examined; statistical comparisons were made using gen-
eralized linear models with a gamma distribution.
RESULTS: A total of 1548 patients were identiﬁed (n =
598 and 950 for inﬂiximab and etanercept respectively).
Inﬂiximab recipients were somewhat older (50.5 vs. 46.6
years for etanercept). Nearly 60% of inﬂiximab patients
experienced an increase in dose at one year, compared to
18% of patients new to etanercept. Inﬂiximab patients
who experienced a dose increase had signiﬁcantly higher
annual RA-related costs than those with no increase
($20,915 vs. $16,713; p < 0.0001). Costs among etaner-
cept patients did not substantially differ based on dose
escalation ($14,482 vs. $13,866 respectively). CON-
CLUSIONS: Patients new to inﬂiximab had much higher
rates of dose escalation relative to etanercept recipients.
These dose increases resulted in signiﬁcantly higher
medical costs at one year.
ARTHRITIS—Quality of Life Studies
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OBJECTIVE: This study aims at translating and adapt-
ing the EQ-5D cross-culturally into Korean (KEQ-5D),
and evaluating its reliability and validity among patients
with various rheumatic diseases. METHODS: The EQ-
5D was translated into Korean by 2 translators and back
into English by another 2 translators. Then lay assessment
was done according to the EuroQol Group’s translation
guidelines. Based on the repeated measure data of 65
patients with rheumatoid arthritis (RA), we examined
test-retest reliability by intra-class correlation (ICC), and
responsiveness by effect size and t-statistic. To evaluate
validity, we recruited 100 patients with RA, 103 with
osteoarthritis (OA), 111 with systemic lupus erythemtous
(SLE), 104 with ﬁbromyalgia syndrome (FMS), and 90
with ankylosing spondylitis (AS). For concurrent validity,
we explored correlation between the KEQ-5D and KEQ-
VAS (visual analog scale), KSF-36 global, utility measures
such as time-trade off (TTO) and standard gamble
(SGM), and disease-speciﬁc measures, including KHAQ
and for RA, KWOMAC for OA, SLEDAI and SLICC for
SLE, KFIQ for FMS, and KBASFI for AS. RESULTS: Test-
retest reliability measured by ICC was 0.635. The effect
size was 0.683. Correlations with KEQ-VAS and SF-36
global were signiﬁcant, however those with TTO and
SGM were not. Correlations with disease-speciﬁc mea-
sures were all signiﬁcant except for SLEAI and SLICC 
in SLE, ranging from -0.477 to -0.603. Correlations
between physical domains of KEQ-5D and KSF-36P were
higher those with KSF-36M, on the contrary, correlation
between anxiety/depression and KSF-36M was higher
than that with KSF-36P in both overall and disease-
speciﬁc analysis. CONCLUSION: These ﬁndings indi-
cated that KEQ-5D had stability and responsiveness, and
moreover, criterion and construct validity were satisfac-
tory. We concluded that KEQ-5D could be applied to
Korean patients with various rheumatic diseases.
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OBJECTIVE: To evaluate process and effects in an imple-
mentation study after the RCT, regarding a health edu-
cation and physical exercise program for older adults
with osteoarthritis (OA) of the knee. Implementation
studies are recommended to assess the feasibility and
effectiveness in real life conditions of health education
programs, after being tested in RCTs. METHODS: Three
types of primary health care providers co-operated in the
study, as well as four major health insurers, anticipating
the future integration of the program in their insurance
policy. Local branches of the providers (n = 18) supported
with a program manual and implementation guidelines,
delivered the program to 157 subjects. Inclusion criteria
were older adults of >55 years of age, with diagnosed OA
of knee. Implementation activities were monitored with
registration forms, questionnaires and interviews with 
the providers. Program-participants completed question-
naires before and immediately after participation. This
design was thought to be adequate, given the objective to
identify the effects of the program in real life conditions
after the RCT. Outcome parameters were pain, mobility,
self-efﬁcacy and OA-knowledge and health care utilisa-
tion. RESULTS: Positive effects occurred for pain (p =
0.06), self-efﬁcacy (p = 0.06), OA-knowledge (p = 0.00),
use of medication (p = 0.00), treatment by phsyiothera-
pist (p = 0.01) and consultation of the general practitioner
(p = 0.01). Effect sizes reported in the former RCT and
the current study, were comparable. All three kinds of
providers contributed to an equal extent to the outcomes.
The implementation strategy contributed to the ﬁdelity in
program delivery. CONCLUSIONS: This implementa-
tion study emphasised that planned co-operation between
researchers, practitioners and policy-makers can con-
tribute to the transfer of research results. In doing so, a
widely recognised gap between research and practice can
be bridged.
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OBJECTIVE: To adapt and validate an Estonian version
of the RAQoL. The measure, developed in the UK,
assesses rheumatoid arthritis (RA) speciﬁc quality of life
(QoL). The aim of the cultural and linguistic adaptation
of the RAQoL is to produce a version with equally good
psychometric properties to existing language versions.
METHODS: Translation consisted of two stages. The
ﬁrst involved six Estonians with non-medical back-
grounds and good English who worked together to agree
a ﬁrst translation of the questionnaire. The group was
attended by one of the authors of the RAQoL who
advised on the precise meaning of items. The appropri-
ateness of wording and clarity of content of the transla-
tion were then evaluated by six healthy people of average
educational level. In the next stage of adaptation 15 RA
patients were interviewed to determine face and content
validity. RESULTS: No major problems were found in
translating the questionnaire into Estonian. Patient inter-
views indicated that the content of the RAQoL was highly
appropriate for Estonian patients, despite differences in
health service provision and culture from the UK. CON-
CLUSION: This is the ﬁrst occasion on which a disease-
speciﬁc QoL questionnaire has been adapted into
Estonian and the results are very encouraging. The ﬁnal
stage of the adaptation will be a formal survey of repro-
ducibility and construct validity of the adapted measure.
The novel aspect of the survey is that data will be col-
lected by means of patient interview and will include a
clinical assessment of functional status and disease activ-
ity at the time of interview. It is intended that the RAQoL
will be used to evaluate interventions and to be included
with the HAQ in a register of patients with rheumatoid
arthritis.
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OBJECTIVES: The aim of this study was to use patients
currently being treated for osteoarthritis to determine 
the utility values for different health outcomes associated
with the use of non-steroidal anti-inﬂammatory drugs
(NSAIDs) or paracetamol. METHODS: A total of 85
patients currently being treated with NSAIDs and/or
paracetamol were recruited to value ﬁve health state sce-
narios using the Assessment of Quality of Life (AQOL)
multi-attribute utility (MAU) instrument. The ﬁve health
states described various health states of osteoarthritis
with varying possible NSAID-related side effects. The
health states were developed using published clinical trial
data and expert opinion. The participant, using the
AQOL MAU, valued each health state. Mean utility
values were derived for each health state using the AQOL
scoring algorithm. RESULTS: Osteoarthritis without gas-
trointestinal (GI) side effects produced the highest mean
utility score (0.69) while the complicated perforation,
ulcer or bleed (PUB) health state produced the lowest
utility (0.20). Higher utility values were seen in the
uncomplicated PUB (0.38) and minor NSAID-type GI
complications (0.48) health states. The health state
describing osteoarthritis managed with paracetamol pro-
duced a lower utility than the health state describing
osteoarthritis managed with traditional NSAIDs (0.36 
vs 0.69)—a result consistent with the relative efﬁcacy of
NSAIDs and paracetamol in the treatment of osteoarthri-
tis. CONCLUSION: The results suggest that there is
potential to improve the quality of life of osteoarthritis
